Skip NavigationSkip to Content

In vitro fidelity of the prototype primate foamy virus (PFV) RT compared to HIV-1 RT

  1. Author:
    Boyer, P. L.
    Stenbak, C. R.
    Hoberman, D.
    Linial, M. L.
    Hughes, S. H.
  2. Author Address

    NCI, HIV Drug Resistance Program, Frederick, MD 21702 USA. Trinity Univ, Dept Biol, San Antonio, TX 78212 USA. Fred Hutchinson Canc Res Ctr, Div Basic Sci A3 015, Seattle, WA 98109 USA.;Hughes, SH, NCI, HIV Drug Resistance Program, Frederick, MD 21702 USA.
    1. Year: 2007
    2. Date: Oct
  1. Journal: Virology
    1. 367
    2. 2
    3. Pages: 253-264
  2. Type of Article: Article
  3. ISSN: 0042-6822
  1. Abstract:

    We compared the in vitro fidelity of wild-type human immunodeficiency virus type-1 (HIV-1) reverse transcriptase (RT) and the prototype foamy virus (PFV) RT. Both enzymes had similar error rates for single nucleotide substitutions; however, PFV RT did not appear to make errors at specific hotspots, like HIV-1 RT. In addition, PFV RT made more deletions and insertions than HIV-1 RT. Although the majority of the missense errors made by HIV-1 RT and PFV RT are different, relatively few of the mutations caused by either enzyme can be explained by a misalignment/slippage mechanism. We suggest that the higher polymerase activity of PFV RT could contribute to the ability of the enzyme to jump to the same or a different template. Published by Elsevier Inc.

    See More

External Sources

  1. DOI: 10.1016/j.virol.2007.05.034
  2. WOS: 000250162900003

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel